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OBJECTIVE — To develop and test a patient questionnaire on treatment satisfaction with
diabetes regimens.
RESEARCH DESIGN AND METHODS — Survey items were developed from commu-
nity clinic focus groups, pretested in patients with diabetes, and examined in two samples of
treated patients.
RESULTS — Sixteen items performed well in assessing treatment experiences: ease and con-
venience, lifestyle burdens, well-being, and medical control. Construct validity was supported
byassociations(P0.05)withtreatmentcomplexity,self-ratedglucosecontrol,healthworries,
and A1C. Internal consistency ranged from 0.89 to 0.95.
CONCLUSIONS — The Diabetes Medication Satisfaction Tool offers a comprehensive as-
sessment of patient acceptability, with diabetes therapy useful for individualizing therapeutic
decision making.
Diabetes Care 32:51–53, 2009
L
ong-term glucose control is challeng-
ing to patients and clinicians alike
(1,2). It is estimated that 30% of all
primary care ofﬁce visits for diabetes are for
symptoms and complications (e.g., dizzi-
ness, exhaustion, vision, and foot com-
plaints), often involving three or more
medications (3,4). Routine assessment of
treatment satisfaction is an important step
toward building and maintaining a thera-
peutic alliance among the patient and fam-
ily,thephysician,andtheothermembersof
the health care team (1,4) to successfully
tailor treatment regimens (5,6).
Whereas the Diabetes Treatment Satis-
factionQuestionnaire(DTSQ)(7)performs
well in measuring patients’ blood glucose
control and overall satisfaction with treat-
ment, it, along with similar-purpose mea-
sures (8–10), does not conceptualize
satisfaction in the context of multiple med-
ications, where regimen complexity and
treatment burden may become important.
Wedevelopedandtestedabriefinstrument
(the Diabetes Medication Treatment Satis-
faction Tool [DMSAT]) designed to mea-
sure patients’ satisfaction with diabetes
medicationtreatmentregimens—fromsim-
ple to complex.
AcopyoftheDMSATinstrumentand
a full report regarding its use can be ac-
cessed at http://www.hmc.psu/diabetes/
research-instrument.html.
RESEARCH DESIGN AND
METHODS— This study involved
item generation, testing, and reﬁnement.
Institutional review board approval was
obtained from the Wake Forest Univer-
sity, and informed consent forms were
completed for all participants. Items for
four concepts identiﬁed in the literature
were “glucose control,” “well-being and
side-effects,” “lifestyle burden,” and
“treatment complexity and convenience”
andwereevaluatedinaseriesofﬁvefocus
groups made up of ﬁve to eight patients
drawn from an evaluation study of com-
munity diabetes clinics in North Carolina
(11). Participants were male and female
and white and nonwhite with simple and
complex medication regimens and A1C
levels that ranged from well controlled to
uncontrolled. The resulting 35-item pro-
totype instrument was administered by
mail to a convenience sample of 75 pa-
tients(theexploratorysample),whowere
treated with diabetes medications at our
study community-care site, to assess item
reliability, mean and distribution, redun-
dancy or uniqueness, skewness, and con-
struct validity. Also examined were item
correlations with A1C level, the Multidi-
mensional Diabetes Questionnaire (12)
lifestyle interference scale, the Medical
Outcomes Studies (MOS) Health Worries
Scale score (13), and global items assess-
ing extent that blood glucose has been
unacceptablyhighorlow.Anitemperfor-
mance score was constructed (0, weak; 1,
moderate; or 2, ideal performance) to
guide item retention. Fifty-ﬁve (73%) pa-
tients completed the survey, and nine
items were removed based on skewness
or redundancy (r  0.75) with other
items.
In the initial test sample, patients of a
large family-medicine practice treated for
diabetes with a recent A1C value within
the last 3 months (the evaluation sample)
wereinvitedtocompletethestudysurvey
packet including the revised 26-item in-
strument and validation instrument de-
scribed above. Medication complexity
was assessed using a score of 0 or 1 (no/
yes) for common diabetes medications
andascoreof0or2(no/yes)forinsulin,a
more demanding regimen. Self-reported
adherence to medications was by recall of
skipped or missed doses over the last 10
days.Packetsweremailedtopatientswith
instructions and a voucher for a 25 USD
gift certiﬁcate. Exploratory factor analysis
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ducted using SAS (version 8; SAS, Cary,
NC) to assess whether the common factor
modelwasappropriate(14)basedonKai-
ser’s sampling adequacy, Scree plot, and
model ﬁt. An oblique rotation of the ini-
tialfactorsolutionwasperformedtoallow
correlated factors. Discriminant validity
of the DMSAT was examined by compar-
ing means across levels of A1C (8% and
8%), treatment complexity (low and
high), self-reported adherence, and MOS
health worries.
For the ﬁnal test sample, another
sample of patients from our community
diabetes care clinics (11) and from an ac-
ademic medical center was recruited to
conduct and evaluate conﬁrmatory factor
analysisoftheDMSATandconﬁrmvalid-
ity. Internal consistency reliability of the
DMSAT scales and total score was also
assessed.
RESULTS— In the evaluation sample,
194 (63%) of 307 eligible patients re-
turned the survey packet; of these, 140
reported current medication use. Partici-
pants had a mean age of 63 years, and
most had completed high school (77%)
and had been diagnosed with diabetes at
least 5 years previously (61%). One-third
(29–39%) were taking one, two, or three
medications for diabetes, with 16% tak-
ing insulin; 14% had a recent A1C
8.0%,and19%ratedtheiradherenceto
their medication regimen in the last 10
days as less than complete. Ten items dis-
played high inter-item correlations
(0.75) and were removed. Initial factor
analysis of the reduced 16-item question-
naire identiﬁed a four-factor structure
consistent with our domains of lifestyle,
medical control, convenience, and well-
beingandexplained75%ofthetotalvari-
ance. Kaiser’s measure (0.92) suggested a
common-factor model. Reliability esti-
mates of the four DMSAT scales and total
score were 0.89 to 0.95. Percents at the
ceiling of the scales were low (1.45–
6.62%). As shown in Table 1, DMSAT
scales and total score discriminated (P 
0.05) between high and low levels of
treatment complexity, self-rated glucose
control, MOS Health Worries Scale score,
and clinical value for recent A1C (8%
vs. 8%) in the expected direction. Cor-
relationoftheDMSATscoreswithcontin-
uous A1C values was 0.24 (P 
0.0049). In the ﬁnal, conﬁrmatory sam-
ple, the DMSAT instrument and survey
packet were obtained from 92 patients.
Conﬁrmatory factor analysis closely rep-
licated the earlier 16-item structure (not
shown). As shown in Table 1, DMSAT
scales and total scores discriminated be-
tween validity groups as in the previous
sample and were highly correlated with
the DTSQ (r  0.68; P  0.001). Unlike
the DMSAT, the DTSQ total score did not
discriminate between levels of treatment
complexity and clinical A1C value.
CONCLUSIONS— The DMSAT is
intended as a brief measure of diabetes
medication treatment satisfaction and
discriminates between important corre-
latesofpatientmanagement.Itperformed
aswellastheDTSQindetectingself-rated
glucose control and health worries but
showed superior properties in correspon-
dence with treatment complexity and
A1C. Note that appraisals of cost of med-
icationsorspeciﬁcsideeffectsthatmaybe
caused by diabetes or its treatment, such
as diminished sexual functioning, bloat-
ing, or weight gain, are not separately as-
sessed and may require assessment
elsewhere. Longitudinal data are needed
to examine responsiveness to interven-
tions.Insummary,webelievethatthe16-
item DMSAT offers a comprehensive
assessment of satisfaction with diabetes
therapy and may aid in individualizing
patient diabetes treatment.
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